Literature DB >> 27080707

Long-term leukopenia in a lung transplanted patient with cystic fibrosis treated with zoledronic acid: a case report.

A Karahasanovic1,2, A-L Thorsteinsson3,4, N H Bjarnason5,6, P Eiken3,4.   

Abstract

Cystic fibrosis (CF) is a serious autosomal recessive genetic disorder associated with chronic lung disease, malabsorption, malnutrition, pancreatic insufficiency and premature respiratory failure. Recent advances in medical science and technology have increased the lifespan of patients with CF, albeit with long-term consequences of the disease, such as osteoporosis, becoming of increasing significance. The medical treatment of osteoporosis in patients with CF or after organ transplantation is still being explored, and no clear guidelines regarding the best choice of bisphosphonate exist. We report a case of a young woman with CF, lung transplantation and low bone mass developing long-term leukopenia after treatment with zoledronic acid. The leukopenia, with a strong affection of the neutrocytes, lasted for 4 months and the condition only went into remission after granulocyte-colony stimulating factor (G-CSF) treatment. It is important to be aware of symptomatic leukopenia in immunosuppressive patients after treatment with zoledronic acid.

Entities:  

Keywords:  Bisphosphonates; Cystic fibrosis; Leukopenia; Lung transplant; Osteoporosis; Zoledronic acid

Mesh:

Substances:

Year:  2016        PMID: 27080707     DOI: 10.1007/s00198-016-3559-x

Source DB:  PubMed          Journal:  Osteoporos Int        ISSN: 0937-941X            Impact factor:   4.507


  19 in total

1.  Treatment of Paget's disease of bone with aminohydroxybutylidene bisphosphonate.

Authors:  D P O'Doherty; D R Bickerstaff; E V McCloskey; N A Hamdy; M N Beneton; S Harris; M Mian; J A Kanis
Journal:  J Bone Miner Res       Date:  1990-05       Impact factor: 6.741

2.  Efficacy of pamidronate for osteoporosis in patients with cystic fibrosis following lung transplantation.

Authors:  R M Aris; G E Lester; J B Renner; A Winders; A Denene Blackwood; R K Lark; D A Ontjes
Journal:  Am J Respir Crit Care Med       Date:  2000-09       Impact factor: 21.405

Review 3.  Cystic fibrosis-related bone disease: insights into a growing problem.

Authors:  Michael S Stalvey; Gregory A Clines
Journal:  Curr Opin Endocrinol Diabetes Obes       Date:  2013-12       Impact factor: 3.243

4.  Nonsustained effect of short-term bisphosphonate therapy on bone turnover three years after renal transplantation.

Authors:  Christoph Schwarz; Christa Mitterbauer; Georg Heinze; Wolfgang Woloszczuk; Martin Haas; Rainer Oberbauer
Journal:  Kidney Int       Date:  2004-01       Impact factor: 10.612

5.  Zoledronic acid prevents bone loss after liver transplantation: a randomized, double-blind, placebo-controlled trial.

Authors:  Bronwyn A L Crawford; Cherie Kam; Julie Pavlovic; Karen Byth; David J Handelsman; Peter W Angus; Geoffrey W McCaughan
Journal:  Ann Intern Med       Date:  2006-02-21       Impact factor: 25.391

6.  [Treatment of Paget's disease with low dose sodium etidronate (5mg/kg/day). Occurrence of reversible transient suspected leukopenia].

Authors:  J Y Reginster; C Gritten; P Diverse; P C Hauwaert; J M Crielaard; R Halleux; P Franchimont
Journal:  Rev Rhum Mal Osteoartic       Date:  1985-03

7.  Zoledronic acid to prevent bone loss in the first 6 months after renal transplantation.

Authors:  Martin Haas; Zdenka Leko-Mohr; Paul Roschger; Josef Kletzmayr; Christoph Schwarz; Christa Mitterbauer; Rudolf Steininger; Stefan Grampp; Klaus Klaushofer; Günter Delling; Rainer Oberbauer
Journal:  Kidney Int       Date:  2003-03       Impact factor: 10.612

Review 8.  Bisphosphonates for osteoporosis in people with cystic fibrosis.

Authors:  Louise S Conwell; Anne B Chang
Journal:  Cochrane Database Syst Rev       Date:  2014-03-14

9.  The effect of 3 versus 6 years of zoledronic acid treatment of osteoporosis: a randomized extension to the HORIZON-Pivotal Fracture Trial (PFT).

Authors:  Dennis M Black; Ian R Reid; Steven Boonen; Christina Bucci-Rechtweg; Jane A Cauley; Felicia Cosman; Steven R Cummings; Trisha F Hue; Kurt Lippuner; Peter Lakatos; Ping Chung Leung; Zulema Man; Ruvie Lou Maria Martinez; Monique Tan; Mary Ellen Ruzycky; Guoqin Su; Richard Eastell
Journal:  J Bone Miner Res       Date:  2012-02       Impact factor: 6.741

Review 10.  Sumatriptan (oral route of administration) for acute migraine attacks in adults.

Authors:  Christopher J Derry; Sheena Derry; R Andrew Moore
Journal:  Cochrane Database Syst Rev       Date:  2012-02-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.